<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/20/mersana-therapeutics-nasdaqmrsn-stock-price-up-10-4.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-20T22:24:41+00:00"/>
    <meta property="og:title" content="Mersana Therapeutics (NASDAQ:MRSN) Stock Price Up 10.4%"/>
    <meta property="og:description" content="Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) rose 10.4% during trading on Wednesday . The stock traded as high as $3.00 and last traded at $2.87, approximately 388,000 shares traded hands during mid-day trading. An increase of 59% from the average daily volume of 243,603 shares. The stock had previously closed at $2.60. MRSN has been […]"/>
  </head>
  <body>
    <article>
      <h1>Mersana Therapeutics (NASDAQ:MRSN) Stock Price Up 10.4%</h1>
      <address><time datetime="2019-11-20T22:24:41+00:00">20 Nov 2019, 22:24</time> by <a rel="author" href="https://www.thecerbatgem.com/author/doug" target="_blank">Doug Wharley</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/mersana-therpts-logo.png"/>
      </figure>
      <p>Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) rose 10.4% during trading on Wednesday . The stock traded as high as $3.00 and last traded at $2.87, approximately 388,000 shares traded hands during mid-day trading. An increase of 59% from the average daily volume of 243,603 shares. The stock had previously closed at $2.60.</p>
      <p>MRSN has been the subject of several analyst reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> upgraded Mersana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Mersana Therapeutics in a report on Thursday, November 7th. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=MRSN">ValuEngine</a> upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $7.83.</p>
      <p>The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.12 and a current ratio of 5.12. The company has a market cap of $131.20 million, a PE ratio of -1.03 and a beta of 1.51. The firm has a fifty day simple moving average of $1.88 and a 200 day simple moving average of $3.18.</p>
      <p>Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. The business had revenue of $0.84 million for the quarter, compared to analyst estimates of $0.50 million. As a group, equities analysts predict that Mersana Therapeutics Inc will post -0.6 EPS for the current fiscal year.</p>
      <p>A number of hedge funds have recently modified their holdings of MRSN. Boxer Capital LLC purchased a new position in Mersana Therapeutics during the second quarter worth approximately $8,440,000. BlackRock Inc. increased its holdings in shares of Mersana Therapeutics by 166.2% during the 2nd quarter. BlackRock Inc. now owns 2,390,463 shares of the company’s stock worth $9,681,000 after buying an additional 1,492,618 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Mersana Therapeutics by 26.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,903,502 shares of the company’s stock worth $7,709,000 after buying an additional 403,011 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Mersana Therapeutics in the 2nd quarter worth $676,000. Finally, Morgan Stanley boosted its holdings in Mersana Therapeutics by 2,211.3% in the second quarter. Morgan Stanley now owns 157,882 shares of the company’s stock valued at $639,000 after acquiring an additional 151,051 shares during the last quarter. 83.98% of the stock is owned by hedge funds and other institutional investors.</p>
      <p><b>Mersana Therapeutics Company Profile</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/MRSN/">NASDAQ:MRSN</a>)</p>
      <p>Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.</p>
      <p>Read More: <a href="https://www.marketbeat.com/financial-terms/what-is-call-option/">Call Option</a></p>
    </article>
  </body>
</html>